RhumbLine Advisers
TSBX

RhumbLine Advisers’s Turnstone Biologics TSBX Stock Holding History

RhumbLine Advisers’s Portfolio TSBX Stock Details TSBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-860
Closed -$2.25K – 4328
2024
Q2 		$2.25K Sell
860
-8,249
-91% -$23.6K ﹤0.01% 4176
2024
Q1 		$23.9K Buy
9,109
+1,868
+26% +$5.35K ﹤0.01% 3741
2023
Q4 		$18.4K Sell
7,241
-589
-8% -$1.54K ﹤0.01% 3783
2023
Q3 		$30.8K Buy
+7,830
New +$69.8K ﹤0.01% 3722

Other funds holding TSBX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

RhumbLine Advisers's TSBX Position: Q3 2024 in Review

RhumbLine Advisers sold out of Turnstone Biologics (TSBX) in Q3 2024, closing a stake of 860 shares — an estimated $2.25K sold.

RhumbLine Advisers first reported a position in TSBX in Q3 2023 and held it in 4 quarters. The position peaked at $30.8K in Q3 2023. 24 funds tracked by Wall St. Rank hold TSBX as of Q3 2024.

  • RhumbLine Advisers reported no remaining Turnstone Biologics position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 860 Turnstone Biologics shares in Q3 2024, an estimated $2.25K.
  • RhumbLine Advisers first reported a position in Turnstone Biologics in Q3 2023 and held it in 4 quarters.
  • RhumbLine Advisers's Turnstone Biologics position peaked at $30.8K in Q3 2023.
  • 24 funds tracked by Wall St. Rank held Turnstone Biologics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.